SCHEMBL6027008

SCHEMBL6027008

CC(C)C1Oc2ccc(Cl)cc2C(C(=O)Nc2ccccc2)N(C2CCCc3ccccc32)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XIAP P98170 5/20 0.41
BIRC3 Q13489 4/20 0.41
BIRC2 Q13490 4/20 0.41
LMNA P02545 2/20 0.39
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
TAS1R2 Q8TE23 1/20 0.38
PPARD Q03181 1/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HTR2C P28335 1/20 0.37
DRD3 P35462 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CNR2 P34972 1/20 0.36
ACKR3 P25106 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5561838 0.89 XIAP (0.42) XIAPBIRC3BIRC2LMNATAS1R3
SCHEMBL5562153 0.85 MEN1 (0.44) XIAPBIRC3BIRC2LMNARAB9A
SCHEMBL5438340 0.83 GHSR (0.41) XIAPBIRC3BIRC2LMNARAB9A
SCHEMBL5561785 0.80 ALDH1A1 (0.38) XIAPBIRC3BIRC2LMNATAS1R3
SCHEMBL5562682 0.80 XIAP (0.40) XIAPBIRC3BIRC2LMNATAS1R3
SCHEMBL5562075 0.78 XIAP (0.39) XIAPBIRC3BIRC2LMNATAS1R3
SCHEMBL5555449 0.75 NPC1 (0.36) XIAPLMNARAB9ANFKB1NFKB2
SCHEMBL5562150 0.74 MEN1 (0.45) XIAPBIRC3BIRC2LMNAMEN1
SCHEMBL5556444 0.74 MEN1 (0.43) XIAPBIRC3BIRC2LMNAMEN1
SCHEMBL5562166 0.74 MAPT (0.42) XIAPLMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060698-B2 Benzoxazepinone derivatives HOFFMANN-LA ROCHE INC. (US) 2006-06-13 US claimed
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. HOFFMANN-LA ROCHE INC. 2004-11-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. BACE1, BACE2, PSEN1 XIAP 4650/4885BIRC3 3111/4885BIRC2 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.